Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives $8.87 Consensus Target Price from Brokerages

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) have been assigned a consensus recommendation of “Hold” from the seventeen research firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, fourteen have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $8.87.

A number of equities research analysts recently commented on SAGE shares. Needham & Company LLC restated a “hold” rating on shares of Sage Therapeutics in a research report on Friday, April 25th. Bank of America started coverage on shares of Sage Therapeutics in a research report on Tuesday, March 11th. They issued an “underperform” rating and a $5.00 price objective for the company. Finally, Wall Street Zen downgraded shares of Sage Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 7th.

Hedge Funds Weigh In On Sage Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in SAGE. SG Americas Securities LLC lifted its holdings in shares of Sage Therapeutics by 57.7% during the 4th quarter. SG Americas Securities LLC now owns 22,498 shares of the biopharmaceutical company’s stock valued at $122,000 after acquiring an additional 8,228 shares in the last quarter. Empowered Funds LLC acquired a new position in Sage Therapeutics in the 4th quarter worth $91,000. Ieq Capital LLC acquired a new position in Sage Therapeutics in the 4th quarter worth $57,000. US Bancorp DE lifted its holdings in Sage Therapeutics by 22.3% in the 4th quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company’s stock worth $67,000 after buying an additional 2,268 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Sage Therapeutics by 2.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 462,309 shares of the biopharmaceutical company’s stock worth $2,510,000 after buying an additional 10,116 shares in the last quarter. Institutional investors and hedge funds own 99.22% of the company’s stock.

Sage Therapeutics Stock Performance

Shares of SAGE opened at $6.70 on Wednesday. Sage Therapeutics has a fifty-two week low of $4.62 and a fifty-two week high of $13.47. The company has a market capitalization of $419.56 million, a price-to-earnings ratio of -1.02 and a beta of 0.18. The firm has a 50-day simple moving average of $6.97 and a 200-day simple moving average of $6.87.

Sage Therapeutics (NASDAQ:SAGE) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.02). Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%. The business had revenue of $14.06 million for the quarter, compared to analyst estimates of $14.12 million. During the same quarter last year, the company posted ($1.80) EPS. Sage Therapeutics’s quarterly revenue was up 78.0% on a year-over-year basis. Equities research analysts forecast that Sage Therapeutics will post -3.52 EPS for the current year.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.